A detailed history of Citigroup Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Citigroup Inc holds 73,490 shares of PTGX stock, worth $2.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
73,490
Previous 21,015 249.7%
Holding current value
$2.83 Million
Previous $728,000 353.57%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$33.72 - $47.33 $1.77 Million - $2.48 Million
52,475 Added 249.7%
73,490 $3.3 Million
Q2 2024

Aug 12, 2024

SELL
$24.66 - $34.8 $4.63 Million - $6.53 Million
-187,626 Reduced 89.93%
21,015 $728,000
Q1 2024

May 10, 2024

BUY
$21.79 - $32.15 $2.96 Million - $4.37 Million
135,938 Added 186.98%
208,641 $6.04 Million
Q4 2023

Feb 09, 2024

SELL
$14.05 - $23.44 $1.06 Million - $1.76 Million
-75,125 Reduced 50.82%
72,703 $1.67 Million
Q3 2023

Nov 09, 2023

BUY
$16.68 - $23.66 $672,320 - $953,663
40,307 Added 37.49%
147,828 $2.47 Million
Q2 2023

Aug 10, 2023

SELL
$18.02 - $29.36 $1.53 Million - $2.49 Million
-84,828 Reduced 44.1%
107,521 $2.97 Million
Q1 2023

May 11, 2023

BUY
$10.78 - $25.38 $477,349 - $1.12 Million
44,281 Added 29.91%
192,349 $4.42 Million
Q4 2022

Feb 09, 2023

SELL
$7.36 - $11.17 $1.23 Million - $1.87 Million
-167,126 Reduced 53.02%
148,068 $1.62 Million
Q3 2022

Nov 10, 2022

SELL
$7.86 - $11.71 $18,117 - $26,991
-2,305 Reduced 0.73%
315,194 $2.66 Million
Q2 2022

Aug 10, 2022

BUY
$7.06 - $25.52 $1.99 Million - $7.19 Million
281,843 Added 790.45%
317,499 $2.51 Million
Q1 2022

May 12, 2022

SELL
$23.34 - $36.08 $2.38 Million - $3.68 Million
-102,095 Reduced 74.12%
35,656 $844,000
Q4 2021

Feb 10, 2022

BUY
$17.63 - $37.1 $1.53 Million - $3.21 Million
86,566 Added 169.12%
137,751 $4.71 Million
Q3 2021

Nov 10, 2021

BUY
$12.95 - $49.69 $662,845 - $2.54 Million
51,185 New
51,185 $907,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.89B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.